Diversity of ATM gene variants: a population-based genome data analysis for precision medicine.


Journal

Human genomics
ISSN: 1479-7364
Titre abrégé: Hum Genomics
Pays: England
ID NLM: 101202210

Informations de publication

Date de publication:
23 08 2019
Historique:
received: 13 02 2019
accepted: 19 08 2019
entrez: 25 8 2019
pubmed: 25 8 2019
medline: 18 3 2020
Statut: epublish

Résumé

Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder that causes deficiency or dysfunction of the ataxia-telangiectasia mutated (ATM) protein. Not only AT patients, but also certain ATM heterozygous mutation carriers show a significantly reduced life expectancy due to cancer and ischemic heart disease; in particular, female carriers having particular alleles have an increased risk of breast cancer. The frequency of such risk heterozygotes at a population level remains to be fully determined, and evidence-based preventive medical guidelines have not yet been established. Using the 3.5KJPNv2 allele frequency panel of Japanese Multi Omics Reference Panel v201902, which shows single-nucleotide variant (SNV) and insertion/deletion (INDEL) allele frequencies from 3552 Japanese healthy individuals, we investigated the diversity of ATM gene variants. We detected 2845 (2370 SNV and 475 INDEL) variants in the ATM gene, including 1338 (1160 SNV and 178 INDEL) novel variants. Also, we found a stop-gained SNV (NC_000008.11:g.108115650G > A (p.Trp266*)) and a disruptive-inframe-deletion (NC_000008.11:g. 108181014AAGAAAAGTATGGATGATCAAG/A (p.Ala1945_Phe1952delinsVal) and two frameshift INDELs (NC_000008.11:g.108119714CAA/C (p.Glu376fs) and NC_000008.11:g.108203577CTTATA/C (p.Ile2629fs)), which would be novel variants predicted to lead to loss of ATM functionality. The combination of population-based biobanking and human genomics provided a novel insight of diversity of ATM gene variants at a population level. For the advancement of precision medicine, such approach will be useful to predict novel pathogenic/likely pathogenic variants in the ATM gene and to establish preventive medical guidelines for certain ATM heterozygotes pertaining to their risk of particular diseases.

Sections du résumé

BACKGROUND
Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder that causes deficiency or dysfunction of the ataxia-telangiectasia mutated (ATM) protein. Not only AT patients, but also certain ATM heterozygous mutation carriers show a significantly reduced life expectancy due to cancer and ischemic heart disease; in particular, female carriers having particular alleles have an increased risk of breast cancer. The frequency of such risk heterozygotes at a population level remains to be fully determined, and evidence-based preventive medical guidelines have not yet been established.
METHODS
Using the 3.5KJPNv2 allele frequency panel of Japanese Multi Omics Reference Panel v201902, which shows single-nucleotide variant (SNV) and insertion/deletion (INDEL) allele frequencies from 3552 Japanese healthy individuals, we investigated the diversity of ATM gene variants.
RESULTS
We detected 2845 (2370 SNV and 475 INDEL) variants in the ATM gene, including 1338 (1160 SNV and 178 INDEL) novel variants. Also, we found a stop-gained SNV (NC_000008.11:g.108115650G > A (p.Trp266*)) and a disruptive-inframe-deletion (NC_000008.11:g. 108181014AAGAAAAGTATGGATGATCAAG/A (p.Ala1945_Phe1952delinsVal) and two frameshift INDELs (NC_000008.11:g.108119714CAA/C (p.Glu376fs) and NC_000008.11:g.108203577CTTATA/C (p.Ile2629fs)), which would be novel variants predicted to lead to loss of ATM functionality.
CONCLUSION
The combination of population-based biobanking and human genomics provided a novel insight of diversity of ATM gene variants at a population level. For the advancement of precision medicine, such approach will be useful to predict novel pathogenic/likely pathogenic variants in the ATM gene and to establish preventive medical guidelines for certain ATM heterozygotes pertaining to their risk of particular diseases.

Identifiants

pubmed: 31443742
doi: 10.1186/s40246-019-0234-2
pii: 10.1186/s40246-019-0234-2
pmc: PMC6708157
doi:

Substances chimiques

ATM protein, human EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins EC 2.7.11.1

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

38

Subventions

Organisme : Japan Radiation Effects Association
ID : FY2018
Pays : International
Organisme : Japan Radiological Society from Bayer Yakuhin
ID : FY2019
Pays : International
Organisme : Marubun Research Promotion Foundation
ID : FY2017-2018
Pays : International

Références

Blood. 2013 May 16;121(20):4036-45
pubmed: 23440242
Orphanet J Rare Dis. 2017 Aug 4;12(1):136
pubmed: 28778179
J Biol Chem. 2011 Mar 18;286(11):9107-19
pubmed: 21149446
Orphanet J Rare Dis. 2016 Nov 25;11(1):159
pubmed: 27884168
Curr Oncol. 2018 Apr;25(2):e176-e180
pubmed: 29719442
Science. 1995 Jun 23;268(5218):1749-53
pubmed: 7792600
N Engl J Med. 1987 May 21;316(21):1289-94
pubmed: 3574400
Hum Genome Var. 2019 Jun 18;6:28
pubmed: 31240104
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
EMBO J. 2006 Aug 9;25(15):3504-14
pubmed: 16858402
Hum Genome Var. 2015 Nov 26;2:15050
pubmed: 27081555
Oncogene. 2007 Dec 10;26(56):7741-8
pubmed: 18066086
Nucleic Acids Res. 2018 Jan 4;46(D1):D551-D557
pubmed: 29069501
BMC Genomics. 2018 Jul 24;19(1):551
pubmed: 30041597
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8021-6
pubmed: 9223307
Nat Commun. 2015 Aug 21;6:8018
pubmed: 26292667
Nature. 2003 Jan 30;421(6922):499-506
pubmed: 12556884
Clin Genet. 2016 Aug;90(2):105-17
pubmed: 26662178
Genome Res. 1999 Aug;9(8):677-9
pubmed: 10447503
Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33
pubmed: 25431634

Auteurs

Hisanori Fukunaga (H)

Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7AE, UK. hfukunaga01@qub.ac.uk.
Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, 247-8533, Japan. hfukunaga01@qub.ac.uk.
Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai, 980-8573, Japan. hfukunaga01@qub.ac.uk.

Yasuyuki Taki (Y)

Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai, 980-8573, Japan.
Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan.

Kevin M Prise (KM)

Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7AE, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH